SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflixs quarterly earnings report is the dominant focus, with traders watching guidance, subscriber engagement and advertising growth amid concerns about competition and a prolonged share-price decline. Many expect further weakness, while bulls argue pessimism is already priced in and see room for a rebound if results or the outlook are stronger than feared.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

The sharp rally has no confirmed company-news catalyst; traders are focused on anticipation of the REGAL Phase 3 final analysis, which is triggered at 80 survival events after the last disclosed count of 78. Some interpret the CEOs anniversary message and SELLASs planned ASH presence as signs of a potential buyout, while others call that speculation and see the move as a rebound or possible short covering.

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Moderna Inc

Moderna is drawing attention as traders position around the full Phase 3 melanoma results for its personalized cancer vaccine, intismeran, with Merck; the prior positive topline result has fueled a sharp rally. Bulls see validation of a broader oncology platform, while skeptics warn that expectations and valuation are stretched and debate a possible sell-the-news reaction.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980 and is headquartered in Cambridge, MA.

Sarepta Therapeutics Inc

SRPTs sharp rebound is being attributed by traders to possible short covering and anticipation of upcoming DM1 and FSHD siRNA data, with Arrowheads RNAi results cited as supportive context. No new Sarepta catalyst is confirmed in the discussion, and some traders view the move as technical or part of broader biotech strength.

IREN Ltd. is a vertically integrated data center business powering the future of Bitcoin, AI and beyond with renewable energy. It is strategically located in renewable-rich, fiber-connected regions across the US and Canada. IREN’s large-scale, grid-connected facilities are purpose-built for the next generation of power-dense computing applications. The company was founded by Daniel Roberts and William Roberts on November 6, 2018, and is headquartered in Sydney, Australia.

IREN Ltd.

IREN Limited

IREN is drawing attention amid a steep selloff in AI-data-center and neocloud stocks, as traders debate financing risks and whether sector-wide concerns apply to the company. Co-CEO Daniel Roberts comments that data centers were built with cash and customer prepayments help fund GPU costs have reassured some bulls, while others remain concerned about dilution, execution and IRENs weak performance versus peers.

General Motors Co. engages in the designing, manufacturing, and selling of trucks, crossovers, cars, and automobile parts, and in providing software-enabled services and subscriptions. It operates through the following segments: GMNA, GMI, Cruise, and GM Financial. The company was founded by William C. Durant on September 16, 1908 and is headquartered in Detroit, MI.

General Motors Company

GMs quarterly earnings beat and new share-repurchase authorization are being overshadowed by a narrowed full-year profit outlook whose midpoint was unchanged, prompting a sharp selloff. Traders are split between viewing the buyback and stronger cash-flow outlook as support and seeing cautious guidance, lower U.S. sales, and cost pressures as reasons for the decline.

Solana is a high-performance Layer 1 blockchain designed for mass adoption by providing a fast, secure, and low-cost environment for decentralized applications. It distinguishes itself by scaling globally without the use of complex sharding or multiple layers, instead maintaining a single, unified ledger to avoid liquidity fragmentation. This architecture allows it to process thousands of transactions per second with sub-second finality, often at a cost of less than a penny per transaction.  The network operates on a unique hybrid model that combines Proof of Stake with an innovation called Proof of History, which functions as a decentralized clock to timestamp transactions. This system reduces the need for constant node communication, allowing the Sealevel engine to run non-conflicting smart contracts in parallel across multiple CPU cores. Further efficiency is gained through the Gulf Stream protocol, which reduces confirmation times by forwarding transactions to validators before the current block is finished.  Founded in 2017 by Anatoly Yakovenko, Solana is now supported by the Switzerland-based Solana Foundation and significant institutional investors like Andreessen Horowitz and Polychain Capital. The platform’s native token, SOL, serves as the primary currency for paying transaction fees, participating in network governance, and securing the system through staking.   Solana has also seen significant institutional adoption ranging from spot Solana ETFs to major partnerships including Visa's 2025 launch of USDC settlement on the network and the tokenization of public equity by firms like Galaxy Digital.

Solana

Solanas volatile pullback and bounce amid broader crypto weakness are driving discussion, with traders watching support and Bitcoins direction. Dip-buyers are accumulating and staking, while bearish traders warn the recovery may fail and expect further downside.

ADMA Biologics, Inc. operates as a biopharmaceutical company, which is engaged in manufacturing, marketing, and developing specialty plasma-derived biologics. The firm operates through the following business segments: ADMA BioManufacturing and Plasma Collection Center. The ADMA BioManufacturing segment consists of immune globulin manufacturing and development operations. The Plasma Collection Center consists of source plasma collection facilities. The company was founded by Adam S. Grossman and Jerrold B. Grossman on June 24, 2004 and is headquartered in Ramsey, NJ.

Adma Biologics Inc

ADMA is drawing attention ahead of its Q3 earnings report, with traders watching whether ASCENIVs growth can offset continued weakness in BIVIGAM and restore confidence in the companys outlook. Some point to improving share-price momentum and buybacks, while others remain cautious because of the earlier short-seller allegations and questions about growth visibility.

Rapport Therapeutics, Inc. engages in the discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. It develops the RAP (receptor associated proteins) technology platform. The company was founded by Steven M. Paul and David Bredt in February 2022 and is headquartered in Boston, MA.

Rapport Therapeutics Inc.

Rapport Therapeutics Inc

Rapports RAP-219 Phase 2 trial in bipolar mania met its primary and secondary endpoints, fueling buying interest and analyst optimism. Traders are debating whether the efficacy signal is strong enough given the modest placebo-adjusted improvement, higher discontinuation rates, and safety questions, contributing to volatile trading.

Myriad Genetics, Inc. is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. It develops and commercializes molecular tests that help patients and providers uncover genetic insights. The company was founded by Walter A. Gilbert, Mark H. Skolnick, and Peter D. Meldrum in May 1991 and is headquartered in Salt Lake City, UT.

Myriad Genetics, Inc.

Myriads agreement to sell its prenatal testing business to Labcorp is driving the sharp rally, with traders viewing the cash transaction as a potential balance-sheet and strategic reset. Bulls welcome the deal and momentum, while skeptics argue the sale removes a revenue-generating business and leaves concerns about declining operations and debt; the transaction remains subject to approval.

statis crypto Watchlist

Bitcoin

Ethereum

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

MELI Stock In Spotlight: Michael Burry Says The Latin American Tech Giant 'Comes Cheap’ Despite Strong Growth 

Equity

Burry disclosed that he increased his position in MELI around the mid-$1,500 level.


Best-Performing ETFs of October 

October's top ETF gainers included the likes of AMDU, ARGT, WGMI and HYDR. These ETFs soared as AI, crypto, and reform optimism drove markets higher.

Argentina-focused Equities Rally After Milei’s Crucial Election Victory — ‘That Was A Big Win,’ Trump Says

HOOD & OPEN: Two Companies Disrupting Their Industry

Capitalism, for all its imperfections, has proven to be an engine of innovation, prosperity, and disruption. As investors, our role is to identify these disruptors. Companies like Robinhood and OpenDoor challenge the status quo. 

MercadoLibre Founder Marcos Galperin Resigns As CEO After 26-Year Run, Delivering 9,000% Return To Investors

Ariel Szarfsztejn, the company's current commerce head, will be the new chief executive beginning on Jan. 1

MercadoLibre Beats Q1 Revenue Estimates: Stock, Retail Sentiment Spike

The strong earnings report follows a substantial $12 billion investment to expand operations across key markets, Brazil, Mexico, and Argentina.


MercadoLibre Jumps On Workforce Expansion Plan, LatAm Investments: Retail Sees Prime Bet Amid Tariff Bloodbath

The company told Bloomberg it will add 28,000 workers by the end of the year.

Global X Funds - Global X MSCI Argentina ETF

Bullish Sentiment

<ul class="summary-bullets"><li>Burry noted that the stock rose from 2022 to 2025, while its price-to-sales ratio remained flat.</li><li>He emphasized that investors did not increase valuation multiples despite steady growth.&nbsp;</li><li>Last week, Goldman Sachs reduced its price target on MercadoLibre to $2,100 from $2,440.</li></ul>Mercado Libre Inc. (MELI) stock drew attention after the “Big Short” fame investor, Michael Burry, highlighted the company’s sustained share-price rally with a largely unchanged price-to-sales multiple between 2022 and 2025.&nbsp;He believes that the stock may still be undervalued despite years of strong execution.<h2 class="st-heading-2">MELI’s Valuation vs Growth Divergence</h2>In his Substack&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://substack.com/home/post/p-198313595">post</a>, Burry showed a chart suggesting that, although the Latin American e-commerce company grew revenue strongly, its valuation remained low, pointing more to a changing investor mood than to weaker business performance.In the post, Burry noted that the stock kept rising for several years even though its price-to-sales ratio did not change much, suggesting a gap between growth expectations and valuation.&nbsp;<figure class="image"><img src="https://news.stocktwits-cdn.com/fiscal_ai_chart_export_15_jpg_9057c0588c.webp" alt="fiscal-ai-chart-export (15).jpg" width="2160" height="2160"></figure>The chart breakdown pointed to a rare pattern: while the share price advanced meaningfully from 2022 through 2025, the price-to-sales ratio stayed unusually stable. That combination typically signals accelerating top-line performance. In this case, it also suggested investors were not aggressively re-rating the business despite consistent growth.“Mercado Libre (MELI) is a clean long-term winner, and the stock comes cheap because it is not based in the United States and does not operate in the United States,” Burry said.&nbsp;Michael Burry said he added MELI to his portfolio at the mid-$1,500 range, describing it as a modest allocation.<a href="https://stocktwits.com/symbol/MELI">Mercado Libre stock</a> edged 0.06% lower overnight, ahead of Tuesday.&nbsp;&nbsp;<h2 class="st-heading-2">MELI’s Q1 Performance&nbsp;</h2>Earlier this month, Mercado Libre delivered strong top-line growth, even as profitability came in slightly below expectations. For the fiscal first quarter, the company reported revenue of $8.85 billion, marking a 49% increase year over year. Earnings per share (EPS) came in at $8.23.&nbsp;While sales surpassed Wall Street’s forecast of $8.3 billion, EPS fell short of the expected $8.47, according to Fiscal AI data, reflecting margin pressure despite strong demand.<h2 class="st-heading-2">Analysts Cut Targets Despite Strong Q1</h2>Following the Q1 earnings, a slew of Wall Street analysts revised their outlook, prompting discussions over its growth trajectory and margin pressure. Last week, Goldman Sachs reduced its price target on MercadoLibre to $2,100 from $2,440, while maintaining a ‘Buy’ rating, as per TheFly.&nbsp;UBS also cut its price target to $1,750 from $2,050, keeping a ‘Neutral’ stance. Meanwhile, JPMorgan adjusted its price target to $1,900 from $2,100 and held its ‘Neutral’ rating.&nbsp;MELI stock has declined by over 21% year-to-date.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/nke-nclh-gis-stocks-hit-52-week-lows-today-why-are-these-consumer-firms-crashing/cZXuO3lReZR">NKE, NCLH, GIS Stocks Hit 52-Week Lows Today: Why Are These Consumer Firms Crashing?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a MercadoLibre, Inc. logo is seen on a smartphone screen.

Mercado Libre Inc. (MELI) stock drew attention after the “Big Short” fame investor, Michael Burry, highlighted the company’s sustained share-price rally with a largely unchanged price-to-sales multiple between 2022 and 2025.&nbsp;He believes that the stoc

Corgi ETF Trust I. - Corgi Digital Banking & Fintech Infrastructure ETF

MercadoLibre Inc

Double beat (rev + EPS)

Revenue beat, EPS miss

EPS beat, revenue miss

Double miss

SpaceX ($SPCX) reports earnings after the close today. What do you expect?

Stocktwits

SpaceX

) reports earnings after the close today. What do you expect?

Stocktwits Polls

$ARGT • ⚪ CONSOLIDATION SMC SETUP
🏛️ INSTITUTIONAL PRE-BELL ORDER FLOW

• Spot: 2,850,667.50 | ⚪ CONSOLIDATION
• Valuation: NEUTRAL
• Dealing Range: 2,734,337.75 ➔ 3,022,930.00
• Refined Demand (+OB): 2,768,187.50 – 2,771,545.50
• Overhead Supply (-OB): Liquidity crest
• Buy-Side Liquidity (PDH): 2,864,157.00 [SWEPT]
• Sell-Side Liquidity (PDL): 2,798,086.00 [UNTOUCHED]
• Imbalance (50% CE): Balanced tape

Full algorithmic levels & execution rules on chart card.
#SmartMoneyConcepts #Trading #PriceAction #OrderFlow

Rajat Patel

$ARGT • ⚪ CONSOLIDATION SMC SETUP
🏛️ INSTITUTIONAL PRE-BELL ORDER FLOW

• Spot: 2,864,034.25 | ⚪ CONSOLIDATION
• Valuation: NEUTRAL
• Dealing Range: 2,734,337.75 ➔ 3,022,930.00
• Refined Demand (+OB): 2,768,187.50 – 2,771,545.50
• Overhead Supply (-OB): Liquidity crest
• Buy-Side Liquidity (PDH): 2,874,826.00 [UNTOUCHED]
• Sell-Side Liquidity (PDL): 2,832,338.00 [SWEPT]
• Imbalance (50% CE): Balanced tape

Full algorithmic levels & execution rules on chart card.
#SmartMoneyConcepts #Trading #PriceAction #OrderFlow

Feed

News

Sentiment

Fundamentals

Info

ARGT Global X Funds - Global X MSCI Argentina ETF

Fundamentals

Latest ARGT News